...
首页> 外文期刊>Journal of neurosurgical sciences >Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies
【24h】

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

机译:使用阶段1,2和3阶段临床研究的汇集数据的血小杂物药代理酶分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Plazomicin is an aminoglycoside with activity against multidrug-resistant Enterobacteriaceae. Plazomicin is dosed on a milligram-per-kilogram-of-body-weight basis and administered by a 30-min intravenous infusion every 24 h, with dose adjustments being made for renal impairment and a body weight (BW) of >= 125% of ideal BW. A population pharmacokinetic analysis was performed to identify patient factors that account for variability in pharmacokinetics and to determine if dose adjustments are warranted based on covariates. The analysis included 143 healthy adults and 421 adults with complicated urinary tract infection (cUTI), acute pyelonephritis, bloodstream infection, or hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) from seven studies (phases 1 to 3). A three-compartment structural pharmacokinetic model with a zero-order rate constant for the intravenous infusion and linear first-order elimination kinetics best described the plasma concentration-time profiles. The base structural model included creatinine clearance (CLCR) as a time-varying covariate for clearance. The covariates included age, BW, height, body surface area, body mass index, sex, race, and disease-related factors. The ranges of the alpha-, beta-, and gamma-phase half-lives for the analysis population were 0.328 to 1.58, 2.77 to 5.38, and 25.8 to 36.5 h, respectively. Total and renal clearances in a typical cUTI or HABP/VABP patient were 4.57 and 4.08 liters/h, respectively. Starting dose adjustments for CLCR are sufficient for minimizing the variation in plasma exposure across patient populations; adjustments based on other covariates are not warranted. The results support initial dosing on a milligram-per-kilogram basis with adjustments for CLCR and BW. Subsequent adjustments based on therapeutic drug management are recommended in certain subsets of patients, including the critically ill and renally impaired.
机译:Plazomicin是一种氨基糖苷,其活性对抗多药肠易杀菌剂的活性。 Plazomicin每千克/千克对千克的体重给药,每24小时通过30分钟的静脉内输注给药,适用于肾损伤和体重(BW)的剂量调节> = 125%理想的bw。进行人口药代动力学分析以确定患者因子因子因动力学的可变性以及确定剂量调整是否根据协变量进行审查。该分析包括143名健康成人和421名成人,具有复杂的泌尿道感染(CUTI),急性肾盂肾炎,血液感染或医院收购的细菌性肺炎/呼吸机相关的细菌肺炎(HABP / vAbp)来自七项研究(阶段1至3) 。具有零阶速率常数的三室结构药代动力学模型,用于静脉内输注和线性首级消除动力学最佳描述等离子体浓度 - 时间曲线。基础结构模型包括肌酐清除(CLCR)作为间隙的时变的协变量。协变量包括年龄,BW,高度,体表面积,体重指数,性别,种族和疾病相关因素。分析人群的α,β-和伽马相半衰期的范围分别为0.328至1.58,2.77至5.38和25.8至36.5小时。典型切割或HABP / VABP患者的总和肾间隙分别为4.57和4.08升/ h。用于CLCR的起始剂量调节足以使患者群体的血浆暴露的变化最小化。不需要基于其他协变量的调整。结果支持以毫克/千克为基础的初始给药,并调整CLCR和BW。在某些患者的子集中建议基于治疗药物管理的后续调整,包括危重生病和肾脏受损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号